Predictors of response to neoadjuvant checkpoint inhibition with chemotherapy in triple-negative breast cancer (TNBC): A meta-analysis of randomized control trials (RCTs)

被引：0
|
作者：
Roy, A. M. [1 ]
Attwood, K. [2 ]
Gandhi, S. [1 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Med Oncol Hematol, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Biostat, Buffalo, NY USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.176
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
158P
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [31] Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials
    Tarantino, Paolo
    Gandini, Sara
    Trapani, Dario
    Criscitiello, Carmen
    Curigliano, Giuseppe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 159
  • [32] Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials
    Ergun, Y.
    Kalkan, Z.
    Ileri, S.
    Tunc, S.
    Urakci, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S212 - S212
  • [33] Responses rates and outcome to neoadjuvant chemotherapy in triple-negative breast cancers (TNBC)
    Neciosup, S. P.
    Ventura, L.
    Gomez, H.
    Pinto, J. A.
    Marcelo, M. J.
    Vidaurre, T.
    Vallejos Sologuren, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials
    Guan, Xiuwen
    Ma, Fei
    Fan, Ying
    Zhu, Wenjie
    Hong, Ruoxi
    Xu, Binghe
    ANTI-CANCER DRUGS, 2015, 26 (08) : 894 - 901
  • [35] TARGETED THERAPY IN TRIPLE-NEGATIVE METASTATIC BREAST CANCER (TNBC) - A SYSTEMATIC REVIEW AND META-ANALYSIS
    Clark, O. A. C.
    Engel, T.
    Paladini, L.
    Ferreira, M. B. A.
    VALUE IN HEALTH, 2013, 16 (07) : A394 - A394
  • [36] Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
    Rizzo, Alessandro
    Cusmai, Antonio
    Massafra, Raffaella
    Bove, Samantha
    Comes, Maria Colomba
    Fanizzi, Annarita
    Rinaldi, Lucia
    Acquafredda, Silvana
    Gadaleta-Caldarola, Gennaro
    Oreste, Donato
    Zito, Alfredo
    Giotta, Francesco
    Lorusso, Vito
    Palmiotti, Gennaro
    CELLS, 2022, 11 (12)
  • [37] Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
    Liu, Miao
    Mo, Qin-Guo
    Wei, Chang-Yuan
    Qin, Qing-Hong
    Huang, Zhen
    He, Jie
    ONCOLOGY LETTERS, 2013, 5 (03) : 983 - 991
  • [38] Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple-negative breast cancer (TNBC)
    Desmoulins, I.
    Chardin, D.
    Richard, C.
    Arnould, L.
    Boidot, R.
    Humbert, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S494 - S494
  • [39] Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
    Ji, Qiao
    Ding, Jingxian
    Hao, Meiqi
    Luo, Nachuan
    Huang, Jiabing
    Zhang, Wenxiong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
    Li, Junjie
    Chen, Li
    Tan, Wei
    Qi, Fang
    Zhang, Yang
    Wang, Zhonghua
    Shao, Zhimin
    CANCER BIOLOGY & MEDICINE, 2022, 19 (05) : 742 - 754
12345